Clinical Trial Update: Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluated trimetazidine for reducing paclitaxel-induced peripheral neuropathy in chemotherapy patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Peripheral Neuropathy

Drugs mentioned

• Trimetazidine (trimetazidine)

Snippet

Sponsor: Minia University | Conditions: Peripheral Neuropathy Due to Chemotherapy | Phase 1, Phase 2 | Status: COMPLETED